Body Pharm's Retatrutide 32 Pen is a pre-filled, 32 mg research-grade device delivering a synthetic triple agonist of human GLP-1, GIP, and glucagon receptors, sold into the UAE market for in vitro use only while the originator molecule (Eli Lilly's LY3437943) remains in Phase 3 trials with no marketing approval in any country as of April 2026. For UAE laboratories looking to buy a retatrutide 32 dose pen, every available SKU, Body Pharm's included, is research-grade material rather than Lilly-manufactured stock. The single most-cited human dataset behind current procurement interest is the 2023 NEJM Phase 2 trial, which reported approximately 24% mean weight loss at 48 weeks at the highest retatrutide dose. The triple-receptor mechanism produces thermogenic weight loss not achievable with single or dual-agonist compounds.
Key Takeaways
- Retatrutide is a triple-agonist peptide (GLP-1R/GIPR/GCGR) with no marketing approval anywhere as of mid-2026; all UAE pens are research-grade material for in vitro use only.
- The 2023 Phase 2 trial (Jastreboff et al., NEJM) reported ~24% mean weight loss at 48 weeks, the anchor dataset for current research interest.
- The Body Pharm 32 Pen delivers 32 weekly doses in pre-filled format; the 64-dose variant suits extended longitudinal studies without lot-change mid-protocol.
- Retatrutide outperforms semaglutide (GLP-1R mono) and tirzepatide (GLP-1R/GIPR dual) on thermogenic and hepatic-lipid endpoints because glucagon-receptor activation drives additional energy expenditure.
- Pen formats eliminate reconstitution variance; vials permit custom-concentration work but introduce pipetting error.
- Confirm your institution's research-use-only documentation before ordering, as import treatment of unregistered biological materials can vary at UAE customs.
This guide covers the pharmacology of retatrutide's three-receptor design, how it compares to semaglutide and tirzepatide, the current regulatory status in the UAE, and how to select between available pen and vial formats for your research protocol.
What Is the Body Pharm Retatrutide 32 Pen?
The Body Pharm Retatrutide 32 Pen is a pre-filled, 32 mg research-grade injector containing synthetic retatrutide peptide (CAS 2381089-83-2). It is supplied for in vitro research use only and delivered ready-to-use without end-user reconstitution. The "32" refers to the pen's titration capacity, letting researchers select fractional doses in laboratory protocols without the volumetric handling errors typical of multi-use vials. This is the main procurement rationale UAE labs cite when sourcing pen-format incretin peptides over lyophilised powder SKUs, pre-filled devices eliminate reconstitution variance in receptor-binding assays.
Some researchers prefer vials for their concentration flexibility, but pens reduce contamination risk and handling steps. That trade-off is worth evaluating against your assay's precision requirements before committing to a format.
Body Pharm does not publish a formal storage datasheet for the 32 pen. Vendor copy lists subcutaneous research use and weekly dosing intervals but omits explicit temperature ranges. Store at 2–8 °C, refrigerated and protected from light, following standard peptide-handling convention rather than manufacturer-specified guidance.
This SKU sits alongside two adjacent formats in the UAE catalogue: the higher-capacity Body Pharm Retatrutide 64 Pen for extended studies, and the same-capacity HD Retatrutide 32 Pen from a competing manufacturer.
Retatrutide's Triple Agonist Mechanism Explained
Retatrutide is a single 39-amino-acid synthetic peptide that activates three receptors simultaneously: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). No other development-stage compound engages all three axes at once as of 2026. Eli Lilly originated it under the development code LY3437943. It remains investigational and has not received marketing approval in any jurisdiction.
GLP-1R agonism drives glucose-dependent insulin secretion, delayed gastric emptying, and central appetite suppression through GLP-1 signalling in pancreatic beta cells and the hypothalamus. This is the same axis semaglutide exploits as a GLP-1R mono-agonist. GIPR co-agonism adds adipocyte-level insulin sensitisation and an additive satiety signal, the dual-receptor profile shared with tirzepatide and visible in dual-agonist research SKUs such as the HD Labs Tirzepatide 30 comparator class.
Why GCGR agonism changes the metabolic profile
GCGR activation is the receptor arm that separates retatrutide from tirzepatide. Glucagon receptor signalling in hepatocytes increases hepatic fatty-acid oxidation and basal energy expenditure while also raising endogenous glucose output. That output effect is counterbalanced in the triple-agonist molecule by the dominant GLP-1R/GIPR insulinotropic activity. The result is net glycaemic improvement alongside thermogenic weight loss not achievable with GLP-1R or GLP-1R/GIPR agonists alone.
The clinical signal behind this mechanism comes from Jastreboff et al., NEJM 2023 (NCT05394519). In that trial, the 12 mg retatrutide cohort recorded approximately 17.5% mean body-weight reduction at 24 weeks and approximately 24% at 48 weeks in adults with obesity. No peer-reviewed Phase 3 data have been published as of mid-2026, so the triple-agonist pharmacology framing still rests on the 2023 Phase 2 dataset plus Lilly pipeline communications.
For researchers cross-referencing format equivalents in the UAE catalogue, the HD Retatrutide 32 Pen carries the same triple-receptor pharmacology in a same-capacity pen from a competing manufacturer, isolating device and purity variables from mechanism.
2026 Retatrutide Research Status
Retatrutide (LY3437943) remains an investigational triple-agonist peptide with no marketing approval anywhere as of mid-2026, including no registration with the UAE Ministry of Health and Prevention (MoHAP). All Body Pharm pens and competing SKUs in the UAE channel are research-grade material for in vitro use, because the originator compound has not completed Phase 3 trials or received regulatory clearance in any jurisdiction.
The anchor human dataset is still Jastreboff et al., NEJM 2023 (NCT05394519), which reported approximately 17.5% mean body-weight reduction at 24 weeks and approximately 24% at 48 weeks in the 12 mg cohort of adults with obesity. Improvements in HbA1c, lipid fractions, and liver enzymes were consistent with simultaneous GLP-1/GIP/glucagon activation improving both glucose control and hepatic lipid clearance. The Phase 2 trial is listed as completed on ClinicalTrials.gov. Procurement specialists verifying status independently should reconfirm record NCT05394519 before citing it in internal documentation.
Phase 3 status as of 2026
Eli Lilly's 2024–2025 pipeline communications describe multiple ongoing Phase 3 obesity and cardiometabolic outcome trials for retatrutide. Primary completion dates are projected for late 2026 to early 2027, with regulatory submission anticipated in the 2027–2028 window. No peer-reviewed Phase 3 outcome papers had appeared in major journals by mid-2026. Data releases from 2024–2025 consist largely of conference abstracts and R&D-day decks rather than full manuscripts, as Phase 3 data remain under embargo pending regulatory submission.
Preclinical and metabolic model relevance
For laboratories running comparative in vitro work, retatrutide is of interest across obesity, type 2 diabetes, and NAFLD/MASH models. Triple GLP-1/GIP/glucagon agonism is hypothesised to outperform dual-incretin compounds on hepatic steatosis and energy expenditure endpoints, because the glucagon receptor arm drives hepatic fatty-acid oxidation independently of the incretin pathway. Dedicated 2024–2026 peer-reviewed animal studies naming retatrutide specifically remain sparse; model design currently borrows from 2022–2023 triple-agonist analogue literature. Researchers triangulating SKUs across the UAE catalogue can cross-reference the HD Labs Retatrutide 10 lyophilised format and the HD Retatrutide 32 Pen for device-matched comparisons.
UAE Retatrutide SKU Comparison, 2026
Three retatrutide SKUs are routinely available to UAE-based laboratories in 2026: the Body Pharm Retatrutide 32 Pen, the HD Retatrutide 32 Pen, and the HD Labs Retatrutide 10 vial. Pen formats deliver pre-titrated subcutaneous-equivalent doses ready for in vitro workflow, with dial increments that match typical research dosing intervals. The lyophilised vial requires bench reconstitution but offers concentration flexibility for dose-response assays, since researchers can prepare custom molarity solutions for EC50 determinations.
| SKU | Total dose | Format | Best-fit use case |
|---|---|---|---|
| Body Pharm Retatrutide 32 Pen | 32 mg | Pre-filled pen | Multi-assay receptor screening across 4–8 week protocols |
| HD Retatrutide 32 Pen | 32 mg | Pre-filled pen | Device-matched cross-vendor comparison at identical dose count |
| HD Labs Retatrutide 10 | 10 mg | Lyophilised vial | Single-experiment or custom-concentration in vitro work |
| Body Pharm Retatrutide 64 Pen | 64 mg | Pre-filled pen | Extended longitudinal models, single-lot continuity |
When to scale up to 64 mg
Labs running extended longitudinal models, NAFLD/MASH triple-agonist comparisons, or parallel cell-line panels typically exhaust a 32-dose pen within a single protocol cycle. The 32 mg supply covers approximately 8 weeks of weekly dosing. For higher-volume programmes, the Body Pharm Retatrutide 64 Pen doubles the dose count in the same device format, covering 16 weeks of continuous dosing without a mid-study lot change.
Lot-to-lot consistency is the practical driver here. Procurement specialists running quantitative endpoints generally prefer one larger pen over two sequential 32-dose units, because batch-to-batch peptide purity fluctuations can skew EC50 measurements.
Pen versus vial in lab workflow
Pens reduce handling steps and contamination risk but constrain concentration to the device's fixed dial increments. Vials permit reconstitution at researcher-chosen molarity, which matters for EC50 determinations and serial dilution panels, but manual pipetting and dissolution steps add technical variability. Your choice depends on whether assay precision or concentration flexibility is the priority.
How Retatrutide Compares to Semaglutide and Tirzepatide
Retatrutide is the only triple-agonist in the incretin research class, engaging GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide acts on GLP-1R alone; tirzepatide on GLP-1R plus GIPR. That receptor breadth is the principal reason retatrutide sits at the top of current incretin-class research interest for UAE laboratories modelling metabolic syndrome, hepatic steatosis, and energy-expenditure pathways. The glucagon arm adds thermogenic and hepatic-lipid-clearance effects absent from single or dual-agonist compounds.
| Compound | Receptor targets | Peak weight reduction (published) | Research maturity (2026) |
|---|---|---|---|
| Semaglutide | GLP-1R | ~15% at 68 weeks (STEP 1, 2021) | Approved clinical analogue (Ozempic, Wegovy) |
| Tirzepatide | GLP-1R + GIPR | ~22.5% at 72 weeks (SURMOUNT-1, 2022) | Approved clinical analogue (Mounjaro, Zepbound) |
| Retatrutide | GLP-1R + GIPR + GCGR | ~17.5% at 24 weeks, ~24% at 48 weeks Phase 2 (NEJM, 2023) | Phase 3 ongoing, no approval as of mid-2026 |
The maturity gap matters for procurement framing. Semaglutide and tirzepatide both have originator clinical products on the UAE market through MoHAP-registered channels, giving researchers approved reference compounds for orthogonal validation. Retatrutide has none. Every retatrutide pen sold into the UAE in 2026, the Body Pharm 32 included, is research-grade material with no Lilly-manufactured clinical counterpart available for cross-checking.
For researchers building a comparative incretin panel, the HD Semaglutide 10 Pen and HD Labs Tirzepatide 30 provide mono- and dual-agonist reference points. The HD Retatrutide 32 Pen and HD Labs Retatrutide 10 cover format variants of the triple-agonist itself. Watch the 24-week versus 68–72-week endpoint asymmetry when modelling dose-response: retatrutide's published trajectory is shorter and steeper, not a like-for-like comparator to semaglutide or tirzepatide late-phase data, because the Phase 2 trial ran for roughly half the duration of the approved-compound efficacy studies.
Procuring Retatrutide for Research in the UAE
Retatrutide procurement in the UAE in 2026 sits in a regulatory grey zone. The compound is not a MoHAP-registered medicine, not named on UAE controlled-substance schedules, and not commercially approved in any jurisdiction as of mid-2026. Every pen on the UAE market, the Body Pharm 32 included, is research-grade material supplied for in vitro and laboratory use only. It is not for human consumption, not a treatment, and not a substitute for an investigational medicinal product imported under MoHAP clinical-trial authorisation.
JCSG handles the Body Pharm 32 alongside the HD Retatrutide 32 Pen and the lower-count HD Labs Retatrutide 10, so a procurement specialist can build a same-category comparison without sourcing across multiple vendors. Orders ship tracked and discreetly packaged. Each batch is logged against vendor-supplied identity and purity documentation, supporting both regulatory compliance and study reproducibility.
UAE Researcher Note
Retatrutide is not approved by MoHAP and is not a scheduled controlled substance by name as of 2026. Import treatment of unregistered biological research materials can vary at UAE customs. Confirm your institution's research-use-only documentation is in order before placing an order, and keep COA records against your in vitro study file.
Related Research Peptides Available in the UAE
Researchers building a metabolic or body-composition protocol around the Body Pharm Retatrutide 32 Pen typically cross-reference adjacent peptide categories stocked through the same UAE channel.
Tesamorelin is a growth-hormone-releasing hormone analogue used in visceral adipose tissue and lipodystrophy research models. GHRH signalling stimulates somatotroph secretion and systemic GH release. The Tesamorelin UAE category includes the Body Pharm Tesamorelin 32 Pen, which mirrors the 32-dose pen format covered in this guide.
IGF-1 LR3 is the long-arginine-3 analogue of insulin-like growth factor 1, used in anabolic signalling and IGF-receptor work. The extended half-life variant permits longer in vitro exposure windows; see the IGF-1 LR3 UAE listings. MOTS-C is a mitochondrial-derived peptide studied in insulin sensitivity and AMPK-pathway research, available via the MOTS-C UAE page. TB500 (thymosin beta-4 fragment) supports tissue-repair and actin-binding research, modulating actin polymerisation and wound-healing signalling; stock is on the TB500 UAE category.
Frequently Asked Questions
What receptors does retatrutide target?
Retatrutide is a synthetic peptide triple agonist of the human GLP-1, GIP, and glucagon receptors (GLP-1R, GIPR, GCGR). It was engineered to activate all three incretin and glucagon pathways simultaneously.
How many doses does the Body Pharm Retatrutide 32 Pen contain?
The Body Pharm Retatrutide 32 Pen is a pre-filled 32 mg device configured for 32 weekly research doses. It is delivered ready-to-use without end-user reconstitution; the pen's dial mechanism dispenses fixed increments across 32 steps.
Is retatrutide approved for human use in the UAE?
No. Retatrutide (LY3437943) is still an investigational compound in active Phase 3 development as of mid-2026. No marketing approvals have been granted in any jurisdiction and no MoHAP registration exists by name. All Body Pharm pens sold into the UAE are research-grade material for in vitro use only.
How does the 32-dose pen differ from the 64-dose pen?
The 32-dose pen supplies roughly half the protocol length of the 64-dose format, suiting shorter dose-response or pilot studies. The 32 mg covers approximately 8 weeks of weekly dosing, while the 64-dose pen extends supply continuity for longer titration arms. Researchers running parallel SKU comparisons can cross-reference the HD Retatrutide 32 Pen for a same-count alternative, or the lower-volume HD Labs Retatrutide 10 vial for small-batch work where custom reconstitution is needed.
What is the CAS number for retatrutide?
The CAS registry number for retatrutide is 2381089-83-2.
Where can a UAE lab order the Body Pharm Retatrutide 32 Pen?
Place a research-use-only order through the Body Pharm Retatrutide 32 Pen product page on JCSG. Tracked UAE delivery and batch documentation are supplied per order, with each shipment including vendor-supplied identity and purity certificates.
Next Steps
Start by confirming your institution's research-use-only documentation and internal compliance requirements with your procurement or regulatory team. Once cleared, compare the Body Pharm 32 Pen against the HD Retatrutide 32 Pen and HD Labs Retatrutide 10 to determine whether pen or vial format best suits your assay design. Place your order through JCSG and retain all batch documentation for your study file.
